Highest-materiality recent filing
Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M
Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.
Niagen Bioscience increases share repurchase authorization to $20M from $10M
Board approved increase of share repurchase program from $10M to $20M.
Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M
Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).
Niagen Bioscience sells ChromaDex Reference Standards business to LGC in all-cash deal
All-cash sale closed Feb 24, 2026; buyer is VHG Labs, part of LGC Group.
Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038
One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
Niagen Bioscience authorizes $10M share repurchase program through October 2027
Board authorized up to $10M in common stock repurchases over ~2 years; expires Oct 31, 2027.
Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).
Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY
Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.
Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth
Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.
Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029
Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.
Stockholders approve 4.75M share increase to equity plan and new ESPP at annual meeting
Amendment to 2017 Equity Incentive Plan adds 4,750,000 shares; approved by 53,046,229 votes for.
Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook
Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).
ChromaDex rebrands as Niagen Bioscience; Nasdaq ticker becomes NAGE
Name change from ChromaDex Corporation to Niagen Bioscience, Inc. effective March 19, 2025.
ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M
Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).
Base salary increased to $650,000 effective Jan 1, 2025; target bonus raised to 75% of base for FY2025.
ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024
Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.
Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.
ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley
Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.
ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M
Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).
ChromaDex auditor Marcum resigns effective Oct 31 due to conflict from CBIZ merger
Marcum LLP resigned as independent auditor effective Oct 31, 2024, citing independence concerns from its impending merger with CBIZ Inc.
Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.
ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M
Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).
ChromaDex appoints James Lee as Interim CFO after Brianna Gerber resignation
Brianna Gerber resigned as CFO and Principal Accounting Officer effective July 12, 2024.
ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12
CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.
All eight director nominees elected: Jaksch, Fried, Rubin, Yu, Ng, Patrick, Cohen, Shahbazi.
ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth
Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).
ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M
Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).
On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024
Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.
On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.
As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.
On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).
Max materiality 0.85 · Median 0.65 · Most common event other_material